Cancer-Fighting CAR-T cells take on tough kidney disease in first human trial
NCT ID NCT07266181
First seen Jan 11, 2026 · Last updated May 12, 2026 · Updated 19 times
Summary
This early-phase study tests whether a special immune therapy called CAR-T can safely treat a severe type of kidney disease that hasn't responded to standard treatments. Five adults with confirmed membranous nephropathy will receive a single infusion of their own re-engineered immune cells. The main goal is to check for serious side effects over the first few months, with a year of follow-up to see if kidney function improves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Nephrology, Xijing Hospital
RECRUITINGXi'an, China, 710012, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.